Apyx Medical Corp. Files 8-K: Agreements, Financials, Equity Sales
Ticker: APYX · Form: 8-K · Filed: Nov 8, 2024 · CIK: 719135
| Field | Detail |
|---|---|
| Company | Apyx Medical Corp (APYX) |
| Form Type | 8-K |
| Filed Date | Nov 8, 2024 |
| Risk Level | medium |
| Pages | 7 |
| Reading Time | 8 min |
| Key Dollar Amounts | $40,000,000, $45,000,000, $5,000,000, $0.001, $1.18 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-results, equity-sale, officer-changes
TL;DR
Apyx Medical 8-K: New deals, financial updates, and stock sales – watch closely.
AI Summary
Apyx Medical Corp. announced on November 4, 2024, the entry into a material definitive agreement. The company also reported its results of operations and financial condition, and disclosed the creation of a direct financial obligation. Additionally, there were unregistered sales of equity securities and changes in its board and officer composition, including compensatory arrangements.
Why It Matters
This filing provides crucial updates on Apyx Medical's financial health, strategic agreements, and equity transactions, which could impact investor decisions and the company's future operations.
Risk Assessment
Risk Level: medium — The filing details material agreements, financial results, and equity sales, which inherently carry financial and operational risks for the company and its investors.
Key Players & Entities
- Apyx Medical Corp. (company) — Filer of the 8-K report
- 20241104 (date) — Conformed period of report
- 20241108 (date) — Filing date
FAQ
What is the nature of the material definitive agreement entered into by Apyx Medical Corp.?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.
What specific financial results or conditions are reported by Apyx Medical Corp.?
The filing states that Apyx Medical Corp. reported its results of operations and financial condition, but the specific financial figures are not detailed in the provided text.
What type of direct financial obligation was created by Apyx Medical Corp.?
The filing mentions the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement, but the specifics of this obligation are not elaborated in the provided text.
Were there any unregistered sales of equity securities by Apyx Medical Corp.?
Yes, the filing explicitly lists 'Unregistered Sales of Equity Securities' as an item of information, indicating such sales occurred.
What changes occurred regarding Apyx Medical Corp.'s directors or officers?
The filing notes 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers,' indicating changes in leadership and related compensation.
Filing Stats: 1,989 words · 8 min read · ~7 pages · Grade level 11 · Accepted 2024-11-08 07:29:10
Key Financial Figures
- $40,000,000 — efined in the Amendment) to exceed: (a) $40,000,000 for the fiscal year ended December 31,
- $45,000,000 — al year ended December 31, 2025; or (b) $45,000,000 for the fiscal year ended December 31,
- $5,000,000 — ot limited to, the Company's receipt of $5,000,000 of net cash proceeds from the issuance
- $0.001 — f the Company's common stock, par value $0.001 per share (the "Common Stock") to Perce
- $1.18 — f Common Stock, at an offering price of $1.18 per share, and (ii) pre-funded warrants
- $1.179 — arrant Shares") at an offering price of $1.179 per Pre-Funded Warrant (which represent
- $7 million — ting related expenses, is approximately $7 million. The Company did not use a placement ag
- $305,761 — Mr. Roman's annual base salary will be $305,761. The Company has not entered into a for
Filing Documents
- form8-k.htm (8-K) — 70KB
- ex4-1.htm (EX-4.1) — 116KB
- ex5-1.htm (EX-5.1) — 23KB
- ex10-1.htm (EX-10.1) — 79KB
- ex10-2.htm (EX-10.2) — 260KB
- ex99-1.htm (EX-99.1) — 260KB
- ex99-2.htm (EX-99.2) — 14KB
- form8-k_001.jpg (GRAPHIC) — 40KB
- ex5-1_001.jpg (GRAPHIC) — 36KB
- ex99-1_001.jpg (GRAPHIC) — 83KB
- ex99-2_001.jpg (GRAPHIC) — 13KB
- 0001493152-24-044154.txt ( ) — 1409KB
- apyx-20241104.xsd (EX-101.SCH) — 3KB
- apyx-20241104_lab.xml (EX-101.LAB) — 33KB
- apyx-20241104_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 8, 2024 Apyx Medical Corporation By: /s/ Matthew Hill Matthew Hill Chief Financial Officer, Secretary and Treasurer